SLC16A1 and lymphoma: The MCT1 inhibitor AZD3965 has completed phase I clinical trials for advanced solid tumors and lymphomas, demonstrating tolerability at doses sufficient to achieve target engagement, and offering promise as a therapeutic agent [39].